A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Conditions: COVID-19; SARS-CoV-2 Infection Interventions: Biological: Recombinant COVID-19 Vaccine (Sf9 Cell); Biological: COVID-19 Vaccine (Vero Cell), Inactivated Sponsors: WestVac Biopharma Co., Ltd.; West China Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Phase 2 Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol
Conditions: COVID-19 Infection Interventions: Biological: ChAd-triCoV/Mac; Other: Control Sponsors: McMaster University; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol
Conditions: COVID-19 Infection Interventions: Biological: ChAd-triCoV/Mac; Other: Control Sponsors: McMaster University; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
Conditions: Respiratory Syncytial Virus Infections Interventions: Biological: RSVPreF3 OA investigational vaccine; Biological: COVID-19 mRNA vaccine Sponsors: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities
ConclusionThe findings show that COVID-19 vaccine trials failed to adequately randomise proportionate numbers of Black adults and adult minority ethnicities. More inclusive practices must be developed and implemented in the recruitment of underserved groups to understand the true impact of COVID-19. (Source: Trials)
Source: Trials - April 12, 2024 Category: Research Source Type: clinical trials
A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.
Conditions: SARS CoV 2 Infection Interventions: Biological: Johnson& Johnson Sponsors: Jens D Lundgren, MD; Ministry of the Interior and Health, Denmark Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Detoxification From the Lipid Tract
Conditions: COVID-19 Vaccine Adverse Reaction Interventions: Device: electroencephalogram biofeedback; Device: electrical brain stimulation; Device: ultra-low frequency transcranial magnetic stimulation; Drug: Sertraline Hydrochloride; Drug: Clonazepam; Drug: Alprazolam; Drug: Metoprolol; Drug: Olanzapine; Drug: Pravastatin Sodium 20 MG; Drug: Sacubitril Valsartan Sodium Hydrate Sponsors: Pachankis, Yang I., M.D.; First Affiliated Hospital of Chongqing Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Collaborative Open Research Initiative Study (CORIS-1)
Conditions: Patient Engagement; COVID-19; Preventable Disease, Vaccine; Burnout, Professional; Emerging Infectious Disease; Artificial Intelligence; Climate Change; Online Education; Mental Health Issue; Substance Use Disorders Interventions: Other: No intervention. This is an observational study Sponsors: Chisquares Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
Conditions: SARS-CoV-2 Interventions: Biological: Investigational mRNA-1273.815; Biological: Licensed Spikevax Vaccine Sponsors: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Covid-19 and Influenza Oral Vaccine Study
Conditions: covid19 Infection; Influenza, Human Interventions: Biological: Covid-19 vaccine; Biological: Influenza vaccine Sponsors: Vaxine Pty Ltd; Australian Respiratory and Sleep Medicine Institute Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Ambispective Observational Multicenter Study on the Efficacy of the Third Dose of Vaccine Anti COVID-19 in Patients Suffering From Solid Tumors Undergoing Oncological Treatment Active.
Conditions: Patients Suffering From Solid Tumors Sponsors: Fondazione IRCCS Policlinico San Matteo di Pavia Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Safety of UFRJvac, Trivalent COVID-19 Vaccine
Conditions: Healthy People Sponsors: Azidus Brasil; Universidade Federal do Rio de Janeiro Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
Conditions: COVID-19 Interventions: Other: Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses Sponsors: IRCCS Sacro Cuore Don Calabria di Negrar Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
Conditions: Vaccine Hesitancy Interventions: Behavioral: Storytelling; Behavioral: Learn More (Active Comparator) Sponsors: University of Massachusetts, Worcester; Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Phase 3 Study of the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
Conditions: COVID-19 Interventions: Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant; Biological: Novavax COVID-19 Vaccine; Biological: Comparator Influenza Vaccine - Fluarix; Biological: Comparator Influenza Vaccine -Fluarix High Dose; Biological: Placebo 0.9% sodium chloride for injection Sponsors: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
